Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers
Abstract Multiple sclerosis (MS) is an immune-mediated demyelinating disease. Epstein-Barr virus (EBV) encodes for the EBNA-1381-452 region that induces autoreactive antibody responses, which are likely critically involved in MS pathogenesis. Here we investigate whether these EBNA-1381-452-specific...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-61751-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234781810720768 |
|---|---|
| author | Hannes Vietzen Laura M. Kühner Sarah M. Berger Markus Ponleitner Marianne Graninger Charlotte Pistorius Christof Jungbauer Markus Reindl Henrieke Saucke Franziska Kauth Eva-Maria Wendel Kevin Rostásy Markus Breu Barbara Kornek Gabriel Bsteh Thomas Berger Paulus Rommer Elisabeth Puchhammer-Stöckl |
| author_facet | Hannes Vietzen Laura M. Kühner Sarah M. Berger Markus Ponleitner Marianne Graninger Charlotte Pistorius Christof Jungbauer Markus Reindl Henrieke Saucke Franziska Kauth Eva-Maria Wendel Kevin Rostásy Markus Breu Barbara Kornek Gabriel Bsteh Thomas Berger Paulus Rommer Elisabeth Puchhammer-Stöckl |
| author_sort | Hannes Vietzen |
| collection | DOAJ |
| description | Abstract Multiple sclerosis (MS) is an immune-mediated demyelinating disease. Epstein-Barr virus (EBV) encodes for the EBNA-1381-452 region that induces autoreactive antibody responses, which are likely critically involved in MS pathogenesis. Here we investigate whether these EBNA-1381-452-specific antibodies can serve as a biomarker to identify at-risk individuals for MS. We quantify EBNA-1381-452-specific antibody titers from 324 relapsing-remitting MS patients and 324 matched controls in longitudinal follow-up plasma samples, starting from the individual’s EBV-seroconversion. In MS patients, significantly elevated EBNA-1381-452-specific IgG titers are identified that are increased already as early as nine months after EBV-seroconversion (OR:5.7; 95% CI: 4.1-8.1; P < 0.0001) and a median 5.4 years prior to MS diagnosis. Especially, the presence of continuously high EBNA-1381-452-specific antibody titers is associated with a more rapid MS diagnosis after EBV-seroconversion (P < 0.0001). Thus, the quantification of EBNA-1381-452-specific IgG antibody levels may provide a prognostic biomarker to determine the individual’s risk for the diagnosis of MS. |
| format | Article |
| id | doaj-art-90b79b7607034daea9b8d82dc8d16b5d |
| institution | Kabale University |
| issn | 2041-1723 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj-art-90b79b7607034daea9b8d82dc8d16b5d2025-08-20T04:03:01ZengNature PortfolioNature Communications2041-17232025-07-0116111110.1038/s41467-025-61751-9Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titersHannes Vietzen0Laura M. Kühner1Sarah M. Berger2Markus Ponleitner3Marianne Graninger4Charlotte Pistorius5Christof Jungbauer6Markus Reindl7Henrieke Saucke8Franziska Kauth9Eva-Maria Wendel10Kevin Rostásy11Markus Breu12Barbara Kornek13Gabriel Bsteh14Thomas Berger15Paulus Rommer16Elisabeth Puchhammer-Stöckl17Center for Virology, Medical University of ViennaCenter for Virology, Medical University of ViennaCenter for Virology, Medical University of ViennaDepartment of Neurology, Medical University of ViennaCenter for Virology, Medical University of ViennaAustrian Red Cross, Blood Service for Vienna, Lower Austria and BurgenlandAustrian Red Cross, Blood Service for Vienna, Lower Austria and BurgenlandClinical Department of Neurology, Medical University of InnsbruckDepartment of Pediatric Neurology, Children´s Hospital Datteln, University Witten/ HerdeckeDepartment of Pediatric Neurology, Children´s Hospital Datteln, University Witten/ HerdeckeDivision of Pediatric Neurology, Department of Pediatrics, OlgahospitalDepartment of Pediatric Neurology, Children´s Hospital Datteln, University Witten/ HerdeckeDepartment of Neurology, Medical University of ViennaDepartment of Neurology, Medical University of ViennaDepartment of Neurology, Medical University of ViennaDepartment of Neurology, Medical University of ViennaDepartment of Neurology, Medical University of ViennaCenter for Virology, Medical University of ViennaAbstract Multiple sclerosis (MS) is an immune-mediated demyelinating disease. Epstein-Barr virus (EBV) encodes for the EBNA-1381-452 region that induces autoreactive antibody responses, which are likely critically involved in MS pathogenesis. Here we investigate whether these EBNA-1381-452-specific antibodies can serve as a biomarker to identify at-risk individuals for MS. We quantify EBNA-1381-452-specific antibody titers from 324 relapsing-remitting MS patients and 324 matched controls in longitudinal follow-up plasma samples, starting from the individual’s EBV-seroconversion. In MS patients, significantly elevated EBNA-1381-452-specific IgG titers are identified that are increased already as early as nine months after EBV-seroconversion (OR:5.7; 95% CI: 4.1-8.1; P < 0.0001) and a median 5.4 years prior to MS diagnosis. Especially, the presence of continuously high EBNA-1381-452-specific antibody titers is associated with a more rapid MS diagnosis after EBV-seroconversion (P < 0.0001). Thus, the quantification of EBNA-1381-452-specific IgG antibody levels may provide a prognostic biomarker to determine the individual’s risk for the diagnosis of MS.https://doi.org/10.1038/s41467-025-61751-9 |
| spellingShingle | Hannes Vietzen Laura M. Kühner Sarah M. Berger Markus Ponleitner Marianne Graninger Charlotte Pistorius Christof Jungbauer Markus Reindl Henrieke Saucke Franziska Kauth Eva-Maria Wendel Kevin Rostásy Markus Breu Barbara Kornek Gabriel Bsteh Thomas Berger Paulus Rommer Elisabeth Puchhammer-Stöckl Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers Nature Communications |
| title | Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers |
| title_full | Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers |
| title_fullStr | Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers |
| title_full_unstemmed | Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers |
| title_short | Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers |
| title_sort | early identification of individuals at risk for multiple sclerosis by quantification of ebna 1381 452 specific antibody titers |
| url | https://doi.org/10.1038/s41467-025-61751-9 |
| work_keys_str_mv | AT hannesvietzen earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT lauramkuhner earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT sarahmberger earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT markusponleitner earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT mariannegraninger earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT charlottepistorius earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT christofjungbauer earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT markusreindl earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT henriekesaucke earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT franziskakauth earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT evamariawendel earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT kevinrostasy earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT markusbreu earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT barbarakornek earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT gabrielbsteh earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT thomasberger earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT paulusrommer earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters AT elisabethpuchhammerstockl earlyidentificationofindividualsatriskformultiplesclerosisbyquantificationofebna1381452specificantibodytiters |